Drug Profile
Amfetamine/guanfacine - Genco Sciences
Latest Information Update: 28 May 2019
Price :
$50
*
At a glance
- Originator Genco Sciences
- Class Acetamides; Amphetamines; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gilles de la Tourette's syndrome
Most Recent Events
- 28 May 2019 No recent reports of development identified for preclinical development in Gilles-de-la-Tourette's-syndrome(In adolescents, In children, In infants, In neonates) in USA
- 07 Dec 2017 Chemical structure information added
- 17 Mar 2016 Guanfacine/amphetamine - Genco Sciences receives Orphan Drug status for Gilles de la Tourette's syndrome in USA